OPXA, Opexa Therapeutics +1,300% Since August

Continuing on the drug makers theme today, but unrelated to H1N1, OPXA is up 1,300% since early August:



The red elipse shows the action today.

The company released news on the success of its Tovaxin MS drug, one where patients do not experience relapses within 1 year, which was common with other drugs: "83 percent of patients taking its experimental multiple sclerosis drug remained relapse-free after a year."

If only this company had options!